Home
News Intelligence
MindMaze Therapeutics Holding SA

MindMaze Therapeutics Holding SA

Healthcare · Artificial Intelligence (AI)

SIX:MMTX
OTCQB:MMTZF

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

Latest announcement

Operational update

Oct 14, 2026

MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026

MindMaze Therapeutics reported increased training exposure and functional improvements in a retrospective home-based rehabilitation programme conducted with Vibra Healthcare.

View summary and FAQs

Announcement Summary
Investor FAQs
Video
Interactive Chat

Latest by type

Financial results: MindMaze Therapeutics Reports H1 2026 Revenue of CHF 0.5 Million and Corporate Update Aug 27, 2026
Financing: MindMaze Completes Organisational Simplification and Updates Neuro.io Financing Aug 10, 2026
Operational update: MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026 Oct 14, 2026
Management change: MindMaze Therapeutics appoints John Krakauer as strategic advisor Aug 12, 2026

Announcements

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

About, from recent announcements

MindMaze Therapeutics Holding SA provides neurorehabilitation solutions combining therapeutic software, sensors and specialised hardware for use from acute hospital care through outpatient treatment and home-based therapy. It announced MindMotion Lite, a tablet-based solution providing the full range of MindMotion neurotherapeutic activities, with teleconsultation and remote management capabilities. The company also reported a multi-site home-based programme involving 177 rehabilitation episodes and 172 adults, in which additional training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone.

Sources: 3 announcements

MindMaze Therapeutics Holding SA

Get alerts

MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026

Latest by type

Announcements

MindMaze Therapeutics announces planned MindMotion Lite launch by end of 2026

MindMaze Therapeutics Announces Upcoming Investor and Industry Conference Appearances

MindMaze Therapeutics Reports H1 2026 Revenue of CHF 0.5 Million and Corporate Update

MindMaze Therapeutics appoints John Krakauer as strategic advisor

MindMaze Completes Organisational Simplification and Updates Neuro.io Financing